Journal
JOURNAL OF CONTROLLED RELEASE
Volume 326, Issue -, Pages 510-522Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2020.07.036
Keywords
Conjugation chemistry; Biomedical nanotechnology; Dimeric prodrug; Nanomedicine; Cancer therapy
Funding
- National Natural Science Foundation of China [81703451]
- Excellent Youth Science Foundation of Liaoning Province [2020-YQ-06]
- Liaoning Revitalization Talents Program [XLYC1907129]
- Science and Technology Major Project of Liaoning [2019JH1/10300004]
- China Postdoctoral Innovative Talents Support Program [BX20190219]
- China Postdoctoral Science Foundation [2020M670794]
Ask authors/readers for more resources
With the rapid development of conjugation chemistry and biomedical nanotechnology, prodrug-based nano-systems (PNS) have emerged as promising drug delivery nanoplatforms. Dimeric prodrug, as an emerging branch of prodrug, has been widely investigated by covalently conjugating two same or different drug molecules. In recent years, great progress has been made in dimeric prodrug-based nanosystems (DPNS) for cancer therapy. Many advantages offered by DPNS have significantly facilitated the delivery efficiency of anticancer drugs, such as high drug loading capacity, favorable pharmacokinetics, tumor stimuli-sensitive drug release and facile combination theranostics. Given the rapid developments in this field, we here outline the latest updates of DPNS in cancer treatment, focusing on dimeric prodrug-encapsulated nanosystems, dimeric prodrug-nanoassemblies and tumor stimuli-responsive DPNS. Moreover, the design principle, advantages and challenges of DPNS for clinical cancer therapy are also highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available